621 related articles for article (PubMed ID: 11115086)
21. Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation.
Millar DJ; Holmes C; Faict D; Dawnay A
Adv Perit Dial; 1998; 14():191-4. PubMed ID: 10649722
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of advanced glycation end products and carbonyl compounds in patients with different conditions of oxidative stress.
Lapolla A; Reitano R; Seraglia R; Sartore G; Ragazzi E; Traldi P
Mol Nutr Food Res; 2005 Jul; 49(7):685-90. PubMed ID: 15926142
[TBL] [Abstract][Full Text] [Related]
23. Quantification of reactive carbonyl compounds in icodextrin-based peritoneal dialysis fluids by combined UHPLC-DAD and -MS/MS detection.
Gensberger-Reigl S; Huppert J; Pischetsrieder M
J Pharm Biomed Anal; 2016 Jan; 118():132-138. PubMed ID: 26540628
[TBL] [Abstract][Full Text] [Related]
24. Low glucose degradation product peritoneal dialysis regimen is associated with lower plasma EN-RAGE and HMGB-1 proinflammatory ligands of receptor for advanced glycation end products.
Opatrna S; Popperlova A; Kalousová M; Zima T
Ther Apher Dial; 2014 Jun; 18(3):309-16. PubMed ID: 24965297
[TBL] [Abstract][Full Text] [Related]
25. Icodextrin metabolites in peritoneal dialysis.
García-López E; Lindholm B
Perit Dial Int; 2009; 29(4):370-6. PubMed ID: 19602601
[No Abstract] [Full Text] [Related]
26. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products.
Boulanger E; Wautier MP; Gane P; Mariette C; Devuyst O; Wautier JL
Nephrol Dial Transplant; 2004 Sep; 19(9):2208-16. PubMed ID: 15213320
[TBL] [Abstract][Full Text] [Related]
27. Glycation and advanced glycation end-product formation with icodextrin and dextrose.
Dawnay AB; Millar DJ
Perit Dial Int; 1997; 17(1):52-8. PubMed ID: 9068023
[TBL] [Abstract][Full Text] [Related]
28. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose.
Thornalley PJ; Langborg A; Minhas HS
Biochem J; 1999 Nov; 344 Pt 1(Pt 1):109-16. PubMed ID: 10548540
[TBL] [Abstract][Full Text] [Related]
29. Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure.
Wiggins KJ; Rumpsfeld M; Blizzard S; Johnson DW
Nephrology (Carlton); 2005 Feb; 10(1):33-6. PubMed ID: 15705179
[TBL] [Abstract][Full Text] [Related]
30. Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids.
Schalkwijk CG; ter Wee PM; Teerlink T
Perit Dial Int; 2000; 20(6):796-8. PubMed ID: 11216581
[No Abstract] [Full Text] [Related]
31. Icodextrin: a review of its use in peritoneal dialysis.
Frampton JE; Plosker GL
Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
[TBL] [Abstract][Full Text] [Related]
32. Influence of icodextrin on plasma and dialysate levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine.
Konings CJ; Schalkwijk CG; van der Sande FM; Leunissen KM; Kooman JP
Perit Dial Int; 2005; 25(6):591-5. PubMed ID: 16411527
[TBL] [Abstract][Full Text] [Related]
33. Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients.
García-López E; Anderstam B; Heimbürger O; Amici G; Werynski A; Lindholm B
Perit Dial Int; 2005; 25(2):181-91. PubMed ID: 15796147
[TBL] [Abstract][Full Text] [Related]
34. 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma.
Erixon M; Wieslander A; Lindén T; Carlsson O; Jönsson JA; Simonsen O; Kjellstrand P
Perit Dial Int; 2009 Feb; 29 Suppl 2():S28-31. PubMed ID: 19270226
[TBL] [Abstract][Full Text] [Related]
35. Icodextrin re-absorption varies with age in children on automated peritoneal dialysis.
Dart A; Feber J; Wong H; Filler G
Pediatr Nephrol; 2005 May; 20(5):683-5. PubMed ID: 15719251
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of icodextrin in peritoneal dialysis patients.
Moberly JB; Mujais S; Gehr T; Hamburger R; Sprague S; Kucharski A; Reynolds R; Ogrinc F; Martis L; Wolfson M
Kidney Int Suppl; 2002 Oct; (81):S23-33. PubMed ID: 12230479
[TBL] [Abstract][Full Text] [Related]
37. PD fluids contain high concentrations of cytotoxic GDPs directly after sterilization.
Erixon M; Lindén T; Kjellstrand P; Carlsson O; Ernebrant M; Forsbäck G; Wieslander A; Jönsson JA
Perit Dial Int; 2004; 24(4):392-8. PubMed ID: 15335155
[TBL] [Abstract][Full Text] [Related]
38. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis.
Friedlander MA; Wu YC; Elgawish A; Monnier VM
J Clin Invest; 1996 Feb; 97(3):728-35. PubMed ID: 8609229
[TBL] [Abstract][Full Text] [Related]
39. Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats.
Kakuta T; Tanaka R; Satoh Y; Izuhara Y; Inagi R; Nangaku M; Saito A; Miyata T
Kidney Int; 2005 Sep; 68(3):1326-36. PubMed ID: 16105068
[TBL] [Abstract][Full Text] [Related]
40. Chemical and physiological relevance of glucose degradation products in peritoneal dialysis.
Mittelmaier S; Niwa T; Pischetsrieder M
J Ren Nutr; 2012 Jan; 22(1):181-5. PubMed ID: 22200439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
